Dendreon Corp. (DNDN:NASDAQ)
Snapshot of Dendreon Corp. (DNDN)
|
OPEN
$28.30
|
PREVIOUS CLOSE
$28.01
|
|
|
DAY HIGH
$28.39
|
DAY LOW
$27.31
|
|
|
52 WEEK HIGH
10/16/09 - $30.42
|
52 WEEK LOW
03/9/09 - $2.55
|
|
|
MARKET CAP
3.2B
|
AVERAGE VOLUME 3 mo
2.1M
|
|
|
DILUTED EPS TTM
$-1.85
|
SHARES OUTSTANDING
115.9M
|
|
|
DNDN Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related business week news
DNDN Details
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company’s product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), an investigational active immunotherapy for the treatment of patients with breast, ovarian, and other solid tumors expressing HER2/neu. The company also has a range of products in preclinical studies, which include CEA for the treatment of breast, lung, and colon cancer; CA-9 (MN) for the treatment of kidney, colon, and cervical cancer; Anti-Serine Protease for the treatment of multiple cancers; and Anti-HLA-DR for the treatment of hematologic malignancies, as well as TRPM8 for the treatment of lung, breast, prostate, and colon cancer. Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington.
DNDN Top Compensated Officers
Key developments for Dendreon Corp. (DNDN)
Dendreon Corp. announced that it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T), the Company’s lead investigational product, to the U.S. Food and Drug Administration (FDA). Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC). If approved by the FDA, PROVENGE would represent the first product in the new therapeutic class known as active cellular immunotherapies. The amended BLA includes data from the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) trial, which was conducted under a Special Protocol Assessment agreement with the FDA. The IMPACT study met its pre-specified primary endpoint demonstrating a statistically significant improvement in overall survival in men with metastatic CRPC. PROVENGE is available through several ongoing clinical trials, including OpenACT, an open label trial enrolling men with metastatic CRPC, ProACT (PROstate cancer Active Cellular immunoTherapy), and NeoACT (NEOadjuvant Active Cellular immunotherapy).
Dendreon Corp. expected to Report Q3 2009 Results on November 11, 2009. This event was calculated by Capital IQ (Created on November 2, 2009).
Dendreon Corp., Q3 2009 Earnings Call, Nov-11-2009
Stock Quotes
| Recently Viewed | |||
| DNDN | $27.54 USD | -0.47 |  |
|---|---|---|---|
| BOOM | $20.21 USD | +0.30 |  |
| WIT | $20.63 USD | +0.15 |  |
| HAL | $30.44 USD | +0.56 |  |
| AV | $13.47 USD | +0.189 |  |
Market data is delayed at least 20 minutes.
DNDN Competitors
| Company | Last | Change |
| Antigenics Inc | $0.76 USD | -0.1363 |
| AVAX Technologies Inc | $0.09 USD | +0.001 |
| Generex Biotechnology Corp | $0.50 USD | -0.005 |
| MannKind Corp | $7.00 USD | +0.12 |
| Vical Inc | $3.05 USD | -0.02 |
| View Industry Companies | ||
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | DNDN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 28,929.0x |
|
| Price/Book | 25.8x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 26,670.0x |
|
|
DNDN |
||
DNDN transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Companies Toolbox
Update/report
Submit private company
Upload your company video
Newsletter
Blogs
RSS feeds
Podcasts
VideosSEARCH FOR JOBS
Post a Job- Seattle, WA-Dendreon
- Seattle, WA-Dendreon
- Morris Plains, NJ-Dendreon
- Seattle, WA-Dendreon
Jobs by SimplyHired
Recommend A Data Enhancement Or Correction
For Dendreon Corp. (DNDN) Snapshot
Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.
Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.
Please indicate which data is in error.
Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.
Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.
